Skip to main content

Table 2 Improvements in OHSA Item 1 scores from randomization to weeks 1, 2, and 4

From: Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension

Improvement, n (%) NOH301 NOH302 NOH306 Pooled
Droxidopa (n = 82) Placebo (n = 80) P value* Droxidopa (n = 50) Placebo (n = 51) P value* Droxidopa (n = 92) Placebo (n = 105) P value* Droxidopa (n = 174) Placebo (n = 185) P value*
Week 1
  ≥ 2 units 53 (64.6) 33 (41.3) 0.004 61 (66.3) 46 (43.8) 0.002 114 (65.5) 79 (42.7) <0.001
  ≥ 50 % 45 (54.9) 28 (35.0) 0.017 51 (55.4) 37 (35.2) 0.006 96 (55.2) 65 (35.1) <0.001
Week 2
  ≥ 2 units 36 (72.0) 29 (56.9) NS 49 (53.3) 47 (44.8) NS 85 (59.9) 76 (48.7) NS
  ≥ 50 % 28 (56.0) 23 (45.1) NS 38 (41.3) 38 (36.2) NS 66 (46.5) 61 (39.1) NS
Week 4
  ≥ 2 units 51 (55.4) 46 (43.8) NS
  ≥ 50 % 44 (47.8) 32 (30.5) 0.025
Week 8
  ≥ 2 units 51 (55.4) 45 (42.9) NS
  ≥ 50 % 47 (51.1) 35 (33.3) 0.023
  1. NS not significant, OHSA Orthostatic Hypotension Symptom Assessment
  2. *P value from the Fisher exact test